Ribociclib and palbociclib, CDK4/6 inhibitors available in Turkey, have become the first-line option in HR(+)/HER2(-) advanced breast cancer patients without visceral crisis when combined with aromatase inhibitors or endocrine therapy (ET), and their use has rapidly increased. Here, CYP19A1 is linked to breast carcinoma.